Efficacy Of Imiquimod Cream Research Articles

Efficacy of Imiquimod Cream Administered Intraperitoneally for Ovarian Metastases in Colorectal Cancer

In this case report, we sought to determine the efficacy of intraperitoneal Imiquimod cream for the treatment of persistent ovarian metastases in colorectal cancer after Avastin-based chemotherapy failure. Topical Imiquimod cream is an immune response modifier. It could trigger skin Langerhan cells (naive dendritic cells) as the priming responsive cell type and initiate a strong Th1-switched anti-tumor cellular immune response. This is a 50-year-old woman with rectal cancer with liver, lung, left adrenal gland and ovarian metastasis, and pelvic carcinomatosis. CEA level decreased after the initial optimal debulking surgery and 12 cycles of chemotherapy. However, CEA level persistently elevated, and CT scan showed progressed carcinomatosis, malignant ascites and diffused metastasis. After intraperitoneal immunomodulatory therapy (IMT) administration with intraperitoneal Interleukin-2 mix Thymoxin on Day 1, and intraperitoneal Imiquimod cream (5% 250 mg in normal saline 2 ml) on Day 2, the amount of drainage ascites gradually decreased, and CEA level dramatically decreased after IMT.

Observation of the efficacy of imiquimod cream in treatment of condyloma acuminatum

Objective To investigate the efficacy of imiquimod cream in treatment of condyloma acuminatum. Methods 90 patients with condyloma acuminatum were randomly divided into treatment group and control group,the treatment group (45 patients) were given imiquimod cream applied externally wart,the control group was applied interferon α-2b wart cream externally,the efficacy and re]apse rate were observed and compared between two groups. Results The total effective rate in treatment group ( 91.1% ) was higher than that in control group (64. 4% ), by statistical analysis, the difference was significant (P ＜ 0.05 ). Treatment group,38 cases of non-recurrence,the recurrence rate was 15. 6% ,in the eontrol group had no recurrence in 29 cases,the recurrence rate was 35.6%, the recurrence rate of the treatment group was significantly lower than control group, the difference was significant ( P ＜ 0.05 ). Conclusion The efficacy of imiquimod treatment had lower recurrence rate and no systemic adverse reactions, local reactions was light, worthy to be popularized and applied. Key words: Condyloma acuminatum; Imiquimod cream; Efficacy

What Lies Beneath? A Lesson for the Clinician. Intraoperative Frozen Section Appearance of Persistent Basal Cell Carcinoma after Apparent Cure with Imiquimod 5% Cream

The Food and Drug Administration (FDA) has approved imiquimod 5% cream for the treatment of nonfacial superficial basal cell carcinoma (BCC), and it has increased in popularity as a nonsurgical approach for the treatment of BCC. Its use for the treatment of superficial BCCs on the trunk, neck, and extremities has been documented in the dermatology and family physician literature. Studies of imiquimod for nodular BCC, on the other hand, have demonstrated suboptimal cure rates according to both clinical and histologic criteria, but little is known about the efficacy of imiquimod cream in the treatment of more extensive lesions, more aggressive BCC subtypes, or treatment in higher risk locations like the face, although the off-label practice of treating facial BCCs with imiquimod is not rare.